News & Updates
Showing Endocrinology articles
Showing

Oral HRS-7535 shows promise in glycaemic control for T2D patients
Use of the once-daily oral HRS-7535, an investigational small-molecule GLP-1 receptor agonist (RA) for type 2 diabetes (T2D) and weight management, demonstrates noninferiority to dapagliflozin for glycated haemoglobin (HbA1c) reduction in Chinese adults with T2D, results of the OUTSTAND-2 phase III trial have shown. Treatment differences are also in favour of HRS-7535, with superiority at the 90-mg dose.

TRE promotes dietary restraint, reduces hunger in adults with obesity, prediabetes
Both the 10-h time restricted eating (TRE) and the 16-h usual eating pattern (UEP) result in improved eating behaviour in adults with obesity and prediabetes in the context of modest and equivalent weight loss, according to a study.

Early PCSK9 inhibition post-MI lowers LDL-C: Does it influence clinical outcomes?
Initiating the PCSK9* inhibitor evolocumab in the cath lab prior to PCI** in patients with acute myocardial infarction (MI) dramatically lowers LDL-C compared with standard care in the phase IV AMUNDSEN trial presented at ESC 2026.





